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Abstract
In 1990 a new approach for vaccination was invented involving injection of plasmid DNA in vivo,
which elicits an immune response to the encoded protein. DNA vaccination can overcome most
disadvantages of conventional vaccine strategies and has potential for vaccines of the future.
However, today 15 years on, a commercial product still has not reached the market. One possible
explanation could be the technique's failure to induce an efficient immune response in humans, but
safety may also be a fundamental issue. This review focuses on the safety of the genetic elements
of DNA vaccines and on the safety of the microbial host for the production of plasmid DNA. We
also propose candidates for the vaccine's genetic elements and for its microbial production host
that can heighten the vaccine's safety and facilitate its entry to the market.
Introduction
Vaccination with purified plasmid DNA involves injection
of the plasmid into the patient to elicit an immune
response to a protein that is encoded on the plasmid [1].
This mini-review focuses upon several aspects of safety of
the DNA molecule itself and of the microorganism used to
manufacture the DNA. The review is not exhaustive but
does raise very important safety issues to be kept in mind
early in the development of DNA vaccines.
DNA vaccination was described in a study in 1990 that
demonstrated the induction of gene expression following
direct intramuscular injection of plasmid DNA in mice
[2]. Since then our understanding of the immunological
mechanisms behind this unexpected result has increased.
This includes identification of immune stimulatory DNA
sequences (ISS) that could explain how DNA vaccines can
evoke an immune response without an adjuvant [3]. The
advantages of DNA vaccines over the traditional attenu-
ated or subunit vaccines are their capacity to induce a
broad spectrum of cellular and humoral immune
responses, their flexible genetic design and low cost of
production in a microbial host. Almost two thousand
papers have been published, and several clinical trials
have been conducted testing DNA vaccines against infec-
tious diseases such as HIV-1 [4], Ebola virus [5] and
malaria [6], or to generate protective immunity against
tumors [7]. Despite this extensive research, a commercial
product has yet to come to the market. One reason for this
may be their failure to induce a strong immune response
in higher animals like primates [8]. Another reason for
their absence from the market may be related to their
safety. Indeed, international regulatory groups have
recently questioned the safety of certain existing DNA vac-
cine constructs and their production systems [9]. While
the main focus of research has previously been on their
functionality and immunological mechanisms, work on
safety aspects most often is put off until later in develop-
ment. By then, making fundamental changes to the DNA
vaccine to improve its safety can be extremely costly and
time-consuming.
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safety to be made during the development of DNA vac-
cines. We highlight safety issues that can be addressed by
the appropriate choice of the vaccine's genetic elements,
of its microbial production host and of the conditions of
manufacture. Special focus will be put on the use of food-
grade host-vector systems that are based on our experience
with the lactic acid bacterium Lactococcus lactis.
The vaccine's genetic elements
The organization of the genetic elements of a DNA vaccine
reflects the plasmid's functionality, its bulk manufacture
and its clinical use in the patient. Thus, the plasmid con-
tains one unit responsible for its propagation in the
microbial host and another unit that drives the expression
of the vaccine gene in the cells of the patient. The genetic
elements of the vaccine are shown in Figure 1, and partic-
ular safety concerns are listed in Table 1.
The unit responsible for plasmid propagation in the
microbial host contains a replication region and a selecta-
ble marker. The replication region allows the mainte-
nance of multiple copies of the plasmid per host cell and
a stable inheritance of the plasmid during bacterial
growth. Furthermore, the replication region also deter-
mines the plasmid's host-range. Because DNA vaccination
involves injection of milligram quantities of plasmid, rep-
lication regions with a narrow host-range can reduce the
probability for spread of the plasmid to the patient's own
flora. A replication region dependent on chromosomally
encoded factors restricts the replication to a single host
strain. One such bio-containment system has been devel-
oped in E. coli based on trans-complementation of a repA-
plasmid replication region by a repA+ host strain [10].
Here, the pWV01-derived vectors cannot replicate in the
absence of the replication factor RepA and thus relies on a
repA+ helper strain. Addition of another ori (origin of rep-
lication) region that is active in mammalian cells allows
prolonged persistence and expression of the vaccine gene
in the transfected tissue. However, uncontrolled expres-
sion of the vaccine gene may induce immunological toler-
ance. Furthermore, persistence and increased spread of
the plasmid may lead to germline transmission as a result
of transfection of sperm cells or oocytes [11]. In fact, PCR
studies have detected vaccine plasmid in the gonads of
vaccinated fetuses and in offspring of these fetuses [12]. A
literature study has identified non-replicating plasmids as
a factor that reduces risk of germline transmission [13].
Accordingly, only prokaryotic and narrow host range rep-
lication regions should be present on vaccine plasmids.
Selectable markers ensure stable inheritance of plasmids
during bacterial growth (Fig. 1). Most vaccine plasmids
rely for this on resistance to antibiotics. Although a pow-
erful selection, resistance genes to antibiotics are discour-
aged by regulatory authorities [14]. The concern is that the
plasmid may transform the patient's microflora and
spread the resistance genes (Table 1). Indeed, there is
much international scientific and regulatory focus on this
issue [15-19]. A non-antibiotic-based marker on vaccine
plasmids for use in E. coli has been developed. This system
is based on the displacement of repressor molecules from
the chromosome to the plasmid, allowing expression of
an essential gene [20]. A selection marker developed in
our laboratory uses an auxotrophic marker in L. lactis
[21,22]. Here, genes encoded on the plasmid relieve the
host's threonine requirement. This selection system is effi-
cient and precludes the use of antibiotics.
The nature of the DNA between the functional genes in
vaccine plasmids is also a safety concern. Specific DNA
sequences or methylation patterns can induce anti-DNA
antibodies and lead to the autoimmune disease systemic
lupus erythematosus [23]. Gilkeson et al. showed that
amongst various organisms bacterial DNA induced the
highest level of DNA-specific antibodies [24]. Therefore, a
reasonable strategy is to minimize the non-functional
sequences in the vaccine plasmid (Table 1). Vaccine plas-
Genetic elements of a plasmid DNA vaccineFigure 1
Genetic elements of a plasmid DNA vaccine. Plasmid 
DNA vaccines consists of a unit for propagation in the 
microbial host and a unit that drives vaccine synthesis in the 
eukaryotic cells. For plasmid DNA production a replication 
region and a selection marker are employed. The eukaryotic 
expression unit comprises an enhancer/promoter region, 
intron, signal sequence, vaccine gene and a transcriptional 
terminator (poly A). Immune stimulatory sequences (ISS) add 
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backbone using an integrase-mediated recombination
technology [25]. In addition, these mini-circles showed
higher in vivo gene expression than a standard plasmid.
Alternatively, we have used a plasmid backbone derived
entirely from food-grade bacterial DNA [26].
The vaccine expression unit consists of the elements nec-
essary for high-level expression and targeting of the vac-
cine component (Figure 1). Most DNA vaccines harbor
promoters and enhancer regions from pathogenic viruses
such as cytomegalo virus (CMV), simian virus 40, or
murine leukaemia virus. For instance, plasmid vaccines
with the CMV promoter have been in clinical trials and are
versatile due to the promoter's activity in a variety of tis-
sues and animal models [27]. As more than 50% of the
population in USA is infected with CMV and as the virus
remains in the body throughout life [28], the use of its
expression signals on vaccine plasmids may induce
recombination events and form new chimeras of CMV.
Promoters and enhancer regions have also been suggested
from housekeeping genes encoding the mouse phosphoe-
nolpyruvate carboxykinase and phosphoglycerate kinase
[29]. However, due to the risk of insertional mutagenesis
and oncogenesis, highly inter-species-conserved
sequences like these should be avoided. This risk can be
reduced by the use of novel synthetic promoters selected
by bioinformatic tools to have a low homology to
sequences potentially present in the recipient. To augment
the promoter activity, introns are introduced, which have
a beneficial effect on the in vivo expression of the vaccine
gene [30]. Most often the intron A from CMV is used.
Here, too, bioinformatics can aid in the design of syn-
thetic introns thereby avoiding sequences already present
in CMV-infected individuals.
For secretion of the vaccine peptide to the extra-cellular
milieu, a signal sequence is positioned in front of the vac-
cine gene. This codes for a signal peptide of about 20–40
amino acids, often derived from bovine proteins such as
the plasminogen activator [31]. However, the fusion of
bovine peptides to an immunogen may induce an immu-
nological cross-reaction. Signal peptides can themselves
induce protective immunity against a microbial pathogen
when administered as a gene vaccine [32]. Apparently, to
avoid undesired immune responses, the nature of the sig-
nal peptide should be considered (Table 1). Statistical
methods like the hidden Markov model have been used to
predict and generate artificial signal peptide sequences for
use in human cells [33]. Such a strategy could be applied
to DNA vaccine development to create more appropriate
signal peptides.
To enhance the potency of a DNA vaccine, ISS's are added
to the plasmid (Figure 1). These are nucleotide hexamers
that interact with Toll-like receptors and add adjuvanticity
[34]. The function of the ISS is independent of its location
on the plasmid and may be present in the prokaryotic
backbone. In fact, Klinman eliminated ISS from the plas-
mid backbone and could partially restore the immuno-
genicity of the plasmid by exogenously added ISS DNA
[35]. Therefore, changing the vector backbone or editing
plasmid components may influence the immune
response due to deletion of the ISS. This, too, emphasizes
the importance of the proper selection of expression vec-
tor early in vaccine development.
Table 1: The safety concerns and possible solutions for plasmid DNA vaccines and their production hosts. A priori each safety concern 
should be addressed as early in development as possible.
Safety concern Possible solution
Genetic elements Transfer of plasmid to host flora Narrow host-range replication region
Non-antibiotic plasmid marker
Germline integration Avoidance of mammalian replication region
Insertional mutagenesis and oncogenesis Artificial DNA for promoter, intron, and signal sequence
Avoidance of human-homologous DNA
Adverse effects of encoded peptide(s) Artificial signal sequences
Avoidance of mammalian replication region
Evaluation of vaccine peptide case-by-case
Induction of autoimmune reactions Minimized plasmids
Production host Endotoxins and biogenic amines Use of gram-positive organism
Transferable antibiotic resistance genes Determination of minimal inhibitory concentrations (MIC's)
Screening for transferability
Genetic instability Analysis of plasmid population by sequencing and mass 
spectrometry
Pathogenicity Use of food-grade organismPage 3 of 5
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The characteristics of the microbial host affect the quality
of the purified DNA [36]. A number of safety concerns
have been advanced concerning the microbial host. As
explained in the following, these include production of
toxins and biogenic amines, transferable antibiotic resist-
ances, and genetic instability, including prophage-
induced promiscuity and rearrangement of plasmid DNA
(Table 1).
For reasons of efficiency, E. coli is usually chosen today as
the production host, with its concomitant benefits and
drawbacks. The benefits include a high DNA yield and
well-established procedures for down-stream processing
of the plasmid. However, as a gram-negative bacterium, E.
coli contains highly immunogenic endotoxin, or lipopol-
ysaccharides (LPS), in its outer membrane. Because of the
net negative charge of both LPS and DNA, these molecules
may be co-purified by the ion exchange principle used in
the purification of plasmid DNA, although commercial
kits do exist that can exclude LPS. On the other hand, the
use of gram-positive hosts, none of which produce LPS,
eliminate this dependency on the absolute efficiency of
LPS-removing kits. Although not as efficient for plasmid
production, L. lactis, as a gram-positive, produces neither
endotoxin nor biogenic amines [37]. Assay for transfera-
ble antibiotic resistances in lactic acid bacteria is today a
routine procedure; common L. lactis research strains are
also genetically robust; and their prophages are of narrow
host-range [38,39].
For large-scale plasmid production, often in about a thou-
sand liters, the fermentation medium must sustain a high-
level production of biomass and of plasmid DNA. At the
same time the medium should be chemically defined and
without components of animal origin that may contain
viruses or prions [40]. Growth in a synthetic medium for
many organisms results in low biomass and low plasmid
yield. Indeed, switching microbial host to increase yield is
complicated as it may lead to unexpected immunological
results because of different DNA methylation patterns.
Consequently, the production strain should be evaluated
in synthetic media at an early point in development. Also
here, L. lactis may be the host of choice due to its efficiency
of growth in chemically defined media [41,42]. Finally,
the genetic integrity of bulk purified plasmid molecules is
today primarily monitored by sequence analysis. How-
ever, to reveal minor populations of molecules such as
multimers or molecules with deletions and insertions,
mass spectrometry should be considered [43].
Conclusion
Plasmid DNA vaccines could be the next generation of
vaccines. As yet, research has focused on building func-
tional DNA vaccines. Therefore, focus on safety has been
limited. In this review we have mentioned some safety
issues to be addressed early in vaccine development.
Using bioinformatic tools, safe eukaryotic expression sig-
nals can be devised in synthetic DNA sequences. Safety
may also be heightened by non-antibiotic plasmid selec-
tion markers, plasmid replication functions with narrow
host-ranges, and minimized plasmids. Using a bio-con-
tainment strategy will also increase the safety of the micro-
bial production host, as will avoidance of toxic substances
like endotoxins. Synthetic growth media should be con-
sidered early in development and will influence choice of
production host. Indeed, it can be easier to address several
of these safety concerns early in vaccine development by
basing the strategy on food-grade bacteria and their DNA,
such as L. lactis and its DNA. Finally, the very availability
of safe host-vector systems will most probably facilitate
the overall acceptance of DNA vaccines.
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